OBJECTIVES: To assess the clinical significance of repeat transurethral resection (reTUR) and surgical margin status after en bloc resection of bladder tumour (ERBT) for pathological T1 (pT1) bladder cancer. PATIENTS AND METHODS: We retrospectively analysed the record of 106 patients with pT1 high-grade bladder cancer who underwent ERBT between April 2013 and February 2021 at multiple institutions. All specimens were reviewed by a genitourinary pathologist. The primary outcome measures were recurrence-free survival (RFS) and progression-free survival (PFS) between patients with and those without reTUR. We also analysed the predictive value of surgical margin on the likelihood of residual tumour on reTUR. RESULTS: A reTUR was performed in 50 of the 106 patients. The 2-year RFS and 3-year PFS were comparable between patients who underwent reTUR and those who did not (55.1% vs 59.9%, P = 0.6, 80.6% vs 82.6%, P = 0.6, respectively). No patient was upstaged to pT2 on reTUR. Regarding the surgical margin status, there were no recurrences at the original site in 51 patients with negative horizontal margins. Cox proportional hazard analysis revealed that a positive vertical margin was an independent prognostic factor of worse PFS. On reTUR, six pTa/is residues were detected in patients with a positive horizontal margin, and three pT1 residues were detected in one patient with a positive vertical margin or other adverse pathological features. CONCLUSIONS: A reTUR after ERBT for pT1 bladder cancer appears not to improve either recurrence or progression. Surgical margin status affects prognosis and reTUR outcomes. A reTUR can be omitted after ERBT in patients with pT1 bladder cancer and negative margins; for those with positive horizontal or vertical margins, reTUR should remain the standard until proven otherwise.

Department of Pathology The Jikei University School of Medicine Tokyo Japan

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology National Hospital Organization Ureshino Medical Center Saga Japan

Department of Urology Saitama Medical Center Saitama Japan

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

BJU Int. 2023 Jul;132(1):112. doi: 10.1111/bju.16005. PubMed

Zobrazit více v PubMed

Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: International consensus panel. Urology 2005; 66: 108–25 PubMed

Cumberbatch MGK, Foerster B, Catto JWF et al. Repeat transurethral resection in non‐muscle‐invasive bladder cancer: A systematic review. Eur Urol 2018; 73: 925–33 PubMed

Babjuk M, Burger M, Capoun O et al. European Association of Urology guidelines on non‐muscle‐invasive bladder cancer (ta, T1, and carcinoma in situ). Eur Urol 2022; 81: 75–94 PubMed

Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol 2006; 175: 1641–4 PubMed

Grimm MO, Steinhoff C, Simon X et al. Effect of routine repeat transurethral resection for superficial bladder cancer: A long‐term observational study. J Urol 2003; 170: 433–7 PubMed

Gontero P, Sylvester R, Pisano F et al. The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/grade 3 bladder cancer treated with bacille Calmette‐Guerin. BJU Int 2016; 118: 44–52 PubMed PMC

Wettstein MS, Baxter NN, Sutradhar R et al. Oncological benefit of re‐resection for T1 bladder cancer: A comparative effectiveness study. BJU Int 2022; 129: 258–68 PubMed

Angulo JC, Palou J, Garcia‐Tello A et al. Second transurethral resection and prognosis of high‐grade non‐muscle invasive bladder cancer in patients not receiving bacillus Calmette‐Guerin. Actas Urol Esp 2014; 38: 164–71 PubMed

Yanagisawa T, Mori K, Motlagh RS et al. En bloc resection for bladder tumors: An updated systematic review and meta‐analysis of its differential effect on its safety, recurrence, and histopathology. J Urol 2022; 207: 754–68 PubMed

Zhou W, Wang W, Wu W et al. Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non‐muscle invasive bladder cancer? A retrospective single‐center study of 251 patients. BMC Urol 2020; 20: 30 PubMed PMC

Soria F, D'Andrea D, Moschini M et al. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well‐selected patients? Urol Oncol 2020; 38: e71–77.e77 PubMed

van Rhijn BW, van der Kwast TH, Alkhateeb SS et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012; 61: 378–84 PubMed

Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990; 66: 543–8 PubMed

Yanagisawa T, Miki J, Sakanaka K et al. Clinical significance of horizontal and vertical margin of En bloc resection for nonmuscle invasive bladder cancer. J Urol 2021; 206: 252–9 PubMed

Yanagisawa T, Miki J, Yorozu T et al. Vertical lamina propria invasion diagnosed by En bloc transurethral resection is a significant predictor of progression for pT1 bladder cancer. J Urol 2021; 205: 1622–8 PubMed

Divrik RT, Sahin AF, Yildirim U et al. Impact of routine second transurethral resection on the long‐term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease‐specific survival: A prospective randomised clinical trial. Eur Urol 2010; 58: 185–90 PubMed

Mori K, Miura N, Babjuk M et al. Low compliance to guidelines in nonmuscle‐invasive bladder carcinoma: A systematic review. Urol Oncol 2020; 38: 774–82 PubMed

Mariappan P, Zachou A, Grigor KM, Edinburgh Uro‐Oncology Group . Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57: 843–9 PubMed

Shoshany O, Mano R, Margel D, Baniel J, Yossepowitch O. Presence of detrusor muscle in bladder tumor specimens‐‐predictors and effect on outcome as a measure of resection quality. Urol Oncol 2014; 32: 40e17–22 PubMed

Sari Motlagh R, Rajwa P, Mori K et al. Comparison of clinicopathologic and oncological outcomes between trans‐urethral En bloc (TUEB) resection and conventional trans‐urethral resection of bladder tumor (cTURBT): A systematic review, meta‐analysis and network meta‐analysis with focus on different energy sources. J Endourol 2022; 36: 535–47 PubMed

Gakis G, Karl A, Bertz S et al. Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non‐muscle‐invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trial. BJU Int 2020; 126: 509–19 PubMed

Krasny SA, Masanskiy IL. Comparison of the safety and efficacy of the new method of en‐bloc and conventional monopolar transurethral resection in the management of primary non‐muscle‐invasive bladder cancer. Onkourologiya 2019; 15: 102–12